COMPUGEN LTD (CGEN) 1.12 -0.02 (-1.75%)
1.12 -0.02 (-1.75%)
IL0010852080 - Common Stock
Fundamental Rating
Taking everything into account, CGEN scores 2 out of 10 in our fundamental rating. CGEN was compared to 64 industry peers in the Life Sciences Tools & Services industry. The financial health of CGEN is medium. Also its profitability is quite bad. CGEN is valued expensive and it does not seem to be growing.
Profitability
Profitability Rating
CGEN has negative profitability rations, so we won't be analyzing them here.
CGEN's Return On Assets of -39.50% is worse than the rest of the industry. The industry average Return On Assets is -13.25%. 83% of the industry peers have a better Return On Assets.
CGEN has a very weak Piotroski-F score of 2.00. This is an indication of health and profitability issues for CGEN.
VS Industry
ROA (-39.5%) VS Industry: 17% outperformed.
-620.54
57.39
Valuation
Valuation Rating
When comparing the price book ratio of CGEN to the average industry price book ratio of 2.39, CGEN is valued rather cheaply.
When comparing the current price to the book value of CGEN, we can conclude it is valued correctly. It is trading at 1.22 times its book value.
CGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CGEN. No positive earnings are expected for the next year.
VS Industry
Price/Book (1.22) VS Industry: 73% outperformed.
52.20
0.23
Growth
Growth Rating
Measured over the past 5 years, CGEN shows a very strong growth in Revenue. The Revenue has been growing by 53.24% on average per year.
The Earnings Per Share is expected to decrease by -2.60% on average over the next 5 years.
Based on estimates for the next 5 years, CGEN will show a decrease in Revenue. The Revenue will decrease by -6.85% on average per year.
CGEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.00%.
The Revenue for CGEN has decreased by -100.00% in the past year. This is quite bad
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -15% | -23.57% | -12.85% | -17.91% | -2.6% |
| Revenue | 53.24% | -30.41% | -100% | -100% | -41.42% | -13.43% | -6.85% |
Health
Health Rating
CGEN has a Current Ratio of 6.16. This indicates that CGEN is financially healthy and has no problem in meeting its short term obligations.
When comparing the Current Ratio to an average industry Current Ratio of 4.94, CGEN is better placed than the average industry peer to meet its short term obligations.
A Quick Ratio of 6.16 indicates that CGEN has no problem at all paying its short term obligations.
When comparing the Quick Ratio to an average industry Quick Ratio of 4.34, CGEN is better placed than the average industry peer to meet its short term obligations.
With a Debt to Equity ratio of 0.00, CGEN is doing better than the averages in the industry. The industry average is at 0.11.
The Piotroski-F score of CGEN is 2.00. This is a very weak score and indicates problems in health and profitability for CGEN.
VS Industry
Debt/Equity (0) VS Industry: 71% outperformed.
3.88
0.00
Quick Ratio (6.16) VS Industry: 69% outperformed.
0.23
40.60
Current Ratio (6.16) VS Industry: 65% outperformed.
0.23
40.60
Dividend
Dividend Rating
No dividends for CGEN!.
COMPUGEN LTD1.12
NASDAQ:CGEN (12/7/2022, 2:30:01 PM)-0.02 (-1.75%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences | ||
| GICS Industry | Life Sciences Tools & Services | ||
| Earnings (Last) | 11-14 2022-11-14/bmo | Earnings (Next) | 02-22 2023-02-22 |
| Ins Owners | N/A | Inst Owners | 25.46% |
| Market Cap | 97.02M | Analysts | 84.62 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | N/A | P/B | 1.22 |
| EV/EBITDA | -0.31 | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | -15% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | -100% |
| EPS Next Y | -23.57% | EPS Next 2Y | -12.85% |
| EPS Next 3Y | -17.91% | EPS Next 5Y | -2.6% |
| Revenue growth 1Y | -100% | Revenue growth 3Y | -30.41% |
| Revenue growth 5Y | 53.24% | Revenue growth Q2Q | -100% |
| Revenue Next Year | -100% | Revenue Next 2Y | -41.42% |
| Revenue Next 3Y | -13.43% | Revenue Next 5Y | -6.85% |
| Current Ratio | 6.16 | Quick Ratio | 6.16 |
| Altman-Z | N/A | F-Score | 2 |
| Debt/Equity | 0 | WACC | 7.97% |
| ROIC/WACC | N/A | ||
| ROA | -39.5% | ROE | N/A |
| ROICexgc | N/A | ROIC | N/A |
| PM | N/A | OM | N/A |
| Asset Turnover | N/A | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA